Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2001 20
2002 54
2003 60
2004 63
2005 103
2006 130
2007 131
2008 123
2009 95
2010 97
2011 81
2012 77
2013 89
2014 66
2015 51
2016 45
2017 30
2018 43
2019 37
2020 45
2021 52
2022 34
2023 35
2024 25
2025 37

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,468 results

Results by year

Filters applied: . Clear all
Page 1
Darbepoetin alfa.
Ibbotson T, Goa KL. Ibbotson T, et al. Drugs. 2001;61(14):2097-104; discussion 2105-6. doi: 10.2165/00003495-200161140-00007. Drugs. 2001. PMID: 11735636 Review.
Darbepoetin alfa is a novel erythropoiesis-stimulating protein developed for the treatment of anaemia associated with chronic kidney disease. ...The mean terminal half-life after subcutaneous administration of darbepoetin alfa was 48.8 hours. In random …
Darbepoetin alfa is a novel erythropoiesis-stimulating protein developed for the treatment of anaemia associated with chronic …
Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, Endo Y, Hara K, Cobitz AR. Akizawa T, et al. Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1155-1165. doi: 10.2215/CJN.16011219. Epub 2020 Jul 28. Clin J Am Soc Nephrol. 2020. PMID: 32723804 Free PMC article. Clinical Trial.
Participants' treatment was switched from current erythropoiesis-stimulating agents (ESAs) to daprodustat 4 mg once daily or darbepoetin alfa 10-60 mug once weekly (on the basis of the prestudy ESA dose). Dose was adjusted every 4 weeks for daprodustat or every 2 we …
Participants' treatment was switched from current erythropoiesis-stimulating agents (ESAs) to daprodustat 4 mg once daily or darbepoetin …
Darbepoetin alfa. Amgen.
Locatelli F, Vecchio LD. Locatelli F, et al. Curr Opin Investig Drugs. 2001 Aug;2(8):1097-104. Curr Opin Investig Drugs. 2001. PMID: 11892920 Review.
The company anticipated a phase III trial in US patients in 2001 for the oncology indication 13977941. In the fourth quarter of 2000, darbepoetin alfa entered phase I trials in Japan. Japanese development of darbepoetin alfa was being conducted by Kiri …
The company anticipated a phase III trial in US patients in 2001 for the oncology indication 13977941. In the fourth quarter of 2000, dar …
Darbepoetin alfa for anemia with myelodysplastic syndrome.
Seastone DJ, Gerds AT. Seastone DJ, et al. Expert Rev Hematol. 2015 Apr;8(2):139-46. doi: 10.1586/17474086.2015.1000854. Epub 2015 Jan 12. Expert Rev Hematol. 2015. PMID: 25579702 Review.
The myelodysplastic syndromes are characterized by refractory cytopenias that lead to symptomatic anemia, bleeding, and increased risk for infections. For almost two decades, the use of darbepoetin and other erythropoietin stimulating agents to treat symptomatic anemia in …
The myelodysplastic syndromes are characterized by refractory cytopenias that lead to symptomatic anemia, bleeding, and increased risk for i …
Darbepoetin Alfa for Late-onset Anemia in Neonates with Rhesus Hemolytic Disease.
Rv S, S R. Rv S, et al. Indian J Pediatr. 2023 Feb;90(2):184-186. doi: 10.1007/s12098-022-04411-w. Epub 2022 Dec 3. Indian J Pediatr. 2023. PMID: 36460815
Erythropoietin stimulating agents (ESA) were tried to manage anemia in these neonates. Darbepoetin alfa (DA) is a long-acting ESA used to treat anemia in premature neonates and in children with chronic kidney disease or on cancer chemotherapy. The authors present th …
Erythropoietin stimulating agents (ESA) were tried to manage anemia in these neonates. Darbepoetin alfa (DA) is a long-acting …
Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
Kelaidi C, Fenaux P. Kelaidi C, et al. Expert Opin Biol Ther. 2010 Apr;10(4):605-14. doi: 10.1517/14712591003709713. Expert Opin Biol Ther. 2010. PMID: 20201708 Review.
IMPORTANCE OF THE FIELD: Anemia is the leading clinical manifestation in myelodysplastic syndromes (MDS), significantly altering quality of life. Darbepoetin alfa has recently been added to the armentarium of erythropoiesis stimulating agents (ESAs) for the treatmen …
IMPORTANCE OF THE FIELD: Anemia is the leading clinical manifestation in myelodysplastic syndromes (MDS), significantly altering quality of …
Pharmacology of darbepoetin alfa.
Macdougall IC, Padhi D, Jang G. Macdougall IC, et al. Nephrol Dial Transplant. 2007 Jun;22 Suppl 4:iv2-iv9. doi: 10.1093/ndt/gfm160. Nephrol Dial Transplant. 2007. PMID: 17526547 Review.
The distinct molecular structure of darbepoetin alfa, in both its amino acid sequence and its carbohydrate content, results in a biologic profile with lower binding affinity, longer circulating half-life, and higher in vivo potency compared with the epoetins. ...Reg …
The distinct molecular structure of darbepoetin alfa, in both its amino acid sequence and its carbohydrate content, results in …
Darbepoetin alfa: a new therapeutic agent for renal anemia.
Macdougall IC. Macdougall IC. Kidney Int Suppl. 2002 May;(80):55-61. doi: 10.1046/j.1523-1755.61.s80.11.x. Kidney Int Suppl. 2002. PMID: 11982814 Free article. Review.
Darbepoetin alfa is a super-sialylated analog of human erythropoietin that has a longer circulating half-life in vivo compared to both native and recombinant hormone. ...Following a clinical research program that began in November 1996, darbepoetin alfa …
Darbepoetin alfa is a super-sialylated analog of human erythropoietin that has a longer circulating half-life in vivo compared …
Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
Wauters I, Vansteenkiste J. Wauters I, et al. Expert Rev Anticancer Ther. 2012 Nov;12(11):1383-90. doi: 10.1586/era.12.117. Epub 2012 Oct 31. Expert Rev Anticancer Ther. 2012. PMID: 23113603 Review.
In an extensive clinical trial program in patients with CIA, darbepoetin alfa (DA) - a long-acting recombinant human erythropoietin - was proven to be very effective in reducing transfusion needs in patients developing CIA. ...Caution is needed in patients with a hi …
In an extensive clinical trial program in patients with CIA, darbepoetin alfa (DA) - a long-acting recombinant human erythropo …
Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia.
Vansteenkiste J, Rossi G, Foote M. Vansteenkiste J, et al. Expert Opin Biol Ther. 2003 Jun;3(3):501-8. doi: 10.1517/14712598.3.3.501. Expert Opin Biol Ther. 2003. PMID: 12783618 Review.
The increased sialic acid content confers a three-fold longer half-life and allows the drug to be administered less frequently than epoetin alfa. Darbepoetin alfa affects the same early haematopoietic cells as epoetin alfa and the endogenous hormone EP …
The increased sialic acid content confers a three-fold longer half-life and allows the drug to be administered less frequently than epoetin …
1,468 results